ArticleClinical rheumatology2018
Altered frequencies of memory B cells in new-onset systemic lupus erythematosus patients.
Article in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 44 citations in OpenAlex.
- The why, what, who and when of B cell depletion in systemic lupus erythematosus: biological rationale, patient stratification and evolving therapeutic modalities.Rheumatology (Oxford, England) · 2026Review
- Integrated immune profiling identifies a coordinated T-cell activation and inflammatory signature in SLE.Lupus science & medicine · 2026Article
- Alterations in peripheral blood B cell subsets and their clinical significance in systemic lupus erythematosus.Scientific reports · 2026Article
- MX2 and IRF7 are Associated With Disease Activity and Renal Involvement in Systemic Lupus Erythematosus: An Exploratory Study.Journal of immunology research · 2026Article
- Immunophenotypes of Systemic Lupus Erythematosus-Features of Clinical and Laboratory Disorders.Doklady. Biochemistry and biophysics · 2025Article
- Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years.Arthritis research & therapy · 2025Article
- Serum level of IFN-λ is elevated in idiopathic inflammatory myopathies.Clinical rheumatology · 2025Article
- Association between peripheral activated naive and double negative 2 B-cell subsets and clinical parameters in lupus nephritis patients.Scandinavian journal of immunology · 2025Article
- TLR10 expression in unswitched memory B associates with the disease activity of patients with systemic lupus erythematosus.Clinical rheumatology · 2025Article
- Genetics of SLE: mechanistic insights from monogenic disease and disease-associated variants.Nature reviews. Nephrology · 2023Review
- Obinutuzumab Effectively Depletes Key B-cell Subsets in Blood and Tissue in End-stage Renal Disease Patients.Transplantation direct · 2023Article
- The rapid inhibition of B-cell activation markers by belimumab was associated with disease control in systemic lupus erythematosus patients.Frontiers in pharmacology · 2023Article
- Human B-cell subset identification and changes in inflammatory diseases.Clinical and experimental immunology · 2022Review
- Autoantibodies in COVID-19 correlate with antiviral humoral responses and distinct immune signatures.Allergy · 2022Article
- Dysfunction of CD27Clinical rheumatology · 2022Article
- Contributions of Immune Cells and Stromal Cells to the Pathogenesis of Systemic Sclerosis: Recent Insights.Frontiers in pharmacology · 2022Review
- Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity.Clinical and experimental immunology · 2021Review
- Human marginal zone B cell development from early T2 progenitors.The Journal of experimental medicine · 2021Article
- Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis.Frontiers in neurology · 2021Review
- Mechanisms of Dysregulated Humoral and Cellular Immunity by SARS-CoV-2.Pathogens (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease, characterized by B cell hyperactivity and pathogenic autoantibodies formation. The objective of this study is to evaluate the distribution of B cell subsets in patients with SLE. We included patients with SLE followed in First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, China. Flow cytometry was used to measure frequencies of B cell subsets, including memory B cells, switched memory B cells, non-switched memory B cells, double-negative memory B cells, and naïve B cells in 130 patients with SLE and 55 healthy controls. The different distributions of B cell subsets were further evaluated by their associations with disease activity and clinical manifestation. SLE patients showed significant alteration of B cell subsets, including lower frequency of non-switched memory B cells and higher double-negative memory B cells. The frequencies of B cell subsets also varied between new-onset SLE patients and chronic SLE patients. Frequencies of total memory B cells, switched memory B cells, and non-switched memory B cells were lower in new-onset SLE patients and frequency of naïve B cells was higher compared with healthy controls. Chronic SLE patients showed increased switched memory B cells and double-negative memory B cells. In addition, switched memory B cells and double-negative B cells were higher in patients with lupus nephritis (LN) regardless of disease activity. Our findings suggested that abnormalities of the B cell subsets homeostasis might contribute to the pathogenesis of SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.